Table 4 Tumour characteristics associated with “Under St Gallen” treatment.
Variable | Category | n Under St Gallen/n included | RRR (95% CI) | p |
|---|---|---|---|---|
Age | (each 10 years) | 1.08 (0.06–1.21) | 0.21 | |
Pathological stage | 0 | 32/36 | 21.6 (7.21–64.5) | < 0.001 |
I | 172/519 | 1 (ref.) | – | |
II | 182/597 | 1.34 (1.00–1.78) | 0.05 | |
Grade of differentiation | I (well differentiated) | 61/260 | 1 (ref.) | – |
II (moderately differentiated) | 97/367 | 1.38 (0.91–2.09) | 0.13 | |
III (poorly differentiated) | 84/222 | 1.88 (1.21–2.93) | 0.005 | |
Missing | 144/303 | 3.72 (2.21–6.29) | < 0.001 | |
Histological type | Ductal | 288/918 | 1 (ref.) | – |
Lobular | 31/82 | 1.40 (0.82–2.41) | 0.22 | |
Papilar | 5/16 | 0.72 (0.23–2.25) | 0.57 | |
Others | 62/136 | 1.96 (1.28–2.99) | 0.002 | |
Progesterone receptors | Negative | 110/262 | 1 (ref.) | – |
Positive | 275/887 | 0.67 (0.49–0.94) | 0.02 | |
Missing | 1/3 | 0.67 (0.06–7.86) | 0.75 | |
Oestrogen receptors | Negative | 51/155 | 1 (ref.) | – |
Positive | 335/996 | 1.13 (0.76–1.67) | 0.54 | |
Missing | 0/1 | – | – | |
HER2 receptors | Negative | 272/953 | 1 (ref.) | – |
Positive | 114/199 | 3.44 (2.40–4.93) | < 0.001 | |
Intrinsic subtype | Luminal A-like | 168/687 | 1 (ref.) | – |
Luminal B-like | 173/324 | 3.63 (2.59–5.09) | < 0.001 | |
HER2 positive (non-luminal) | 28/52 | 4.38 (2.23–8.60) | < 0.001 | |
Triple negative (ductal) | 17/89 | 0.70 (0.39–1.28) | 0.25 |
